vs
Federal Realty Investment Trust（FRT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Federal Realty Investment Trust的季度营收约是Ultragenyx Pharmaceutical Inc.的1.6倍（$336.0M vs $207.3M），Federal Realty Investment Trust净利率更高（38.6% vs -62.0%，领先100.6%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 8.7%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 6.5%）
Federal Realty Investment Trust是一家专业房地产投资信托基金，核心投资标的为购物中心类商业物业，资产布局覆盖美国东北部、大西洋中部地区、加利福尼亚州及南佛罗里达区域，在当地商业不动产投资领域拥有丰富的运营经验。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
FRT vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $336.0M | $207.3M |
| 净利润 | $129.7M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 53.8% | -54.7% |
| 净利率 | 38.6% | -62.0% |
| 营收同比 | 8.7% | 25.9% |
| 净利润同比 | 103.5% | 3.5% |
| 每股收益（稀释后） | $1.49 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $336.0M | — | ||
| Q4 25 | $336.0M | $207.3M | ||
| Q3 25 | $322.3M | $159.9M | ||
| Q2 25 | $311.5M | $166.5M | ||
| Q1 25 | $309.2M | $139.3M | ||
| Q4 24 | $311.4M | $164.6M | ||
| Q3 24 | $303.6M | $139.5M | ||
| Q2 24 | $296.1M | $147.0M |
| Q1 26 | $129.7M | — | ||
| Q4 25 | $129.7M | $-128.6M | ||
| Q3 25 | $61.6M | $-180.4M | ||
| Q2 25 | $155.9M | $-115.0M | ||
| Q1 25 | $63.8M | $-151.1M | ||
| Q4 24 | $65.5M | $-133.2M | ||
| Q3 24 | $61.0M | $-133.5M | ||
| Q2 24 | $112.0M | $-131.6M |
| Q1 26 | 53.8% | — | ||
| Q4 25 | 53.8% | -54.7% | ||
| Q3 25 | 34.3% | -106.9% | ||
| Q2 25 | 65.1% | -64.8% | ||
| Q1 25 | 35.0% | -102.6% | ||
| Q4 24 | 35.1% | -74.3% | ||
| Q3 24 | 34.9% | -94.6% | ||
| Q2 24 | 53.0% | -79.1% |
| Q1 26 | 38.6% | — | ||
| Q4 25 | 38.6% | -62.0% | ||
| Q3 25 | 19.1% | -112.8% | ||
| Q2 25 | 50.0% | -69.0% | ||
| Q1 25 | 20.6% | -108.5% | ||
| Q4 24 | 21.0% | -80.9% | ||
| Q3 24 | 20.1% | -95.7% | ||
| Q2 24 | 37.8% | -89.5% |
| Q1 26 | $1.49 | — | ||
| Q4 25 | $1.49 | $-1.28 | ||
| Q3 25 | $0.69 | $-1.81 | ||
| Q2 25 | $1.78 | $-1.17 | ||
| Q1 25 | $0.72 | $-1.57 | ||
| Q4 24 | $0.74 | $-1.34 | ||
| Q3 24 | $0.70 | $-1.40 | ||
| Q2 24 | $1.32 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $107.4M | $421.0M |
| 总债务越低越好 | $5.0B | — |
| 股东权益账面价值 | $3.2B | $-80.0M |
| 总资产 | $9.1B | $1.5B |
| 负债/权益比越低杠杆越低 | 1.53× | — |
8季度趋势，按日历期对齐
| Q1 26 | $107.4M | — | ||
| Q4 25 | $107.4M | $421.0M | ||
| Q3 25 | $111.3M | $202.5M | ||
| Q2 25 | $177.0M | $176.3M | ||
| Q1 25 | $109.2M | $127.1M | ||
| Q4 24 | $123.4M | $174.0M | ||
| Q3 24 | $97.0M | $150.6M | ||
| Q2 24 | $103.2M | $480.7M |
| Q1 26 | $5.0B | — | ||
| Q4 25 | $5.0B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $-80.0M | ||
| Q3 25 | $3.2B | $9.2M | ||
| Q2 25 | $3.2B | $151.3M | ||
| Q1 25 | $3.2B | $144.2M | ||
| Q4 24 | $3.2B | $255.0M | ||
| Q3 24 | $3.1B | $346.8M | ||
| Q2 24 | $3.0B | $432.4M |
| Q1 26 | $9.1B | — | ||
| Q4 25 | $9.1B | $1.5B | ||
| Q3 25 | $8.9B | $1.2B | ||
| Q2 25 | $8.6B | $1.3B | ||
| Q1 25 | $8.6B | $1.3B | ||
| Q4 24 | $8.5B | $1.5B | ||
| Q3 24 | $8.5B | $1.5B | ||
| Q2 24 | $8.4B | $1.6B |
| Q1 26 | 1.53× | — | ||
| Q4 25 | 1.53× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.42× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $622.4M | $-99.8M | ||
| Q3 25 | $147.8M | $-91.4M | ||
| Q2 25 | $150.7M | $-108.3M | ||
| Q1 25 | $179.0M | $-166.5M | ||
| Q4 24 | $574.6M | $-79.3M | ||
| Q3 24 | $144.1M | $-67.0M | ||
| Q2 24 | $169.7M | $-77.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 4.80× | — | ||
| Q3 25 | 2.40× | — | ||
| Q2 25 | 0.97× | — | ||
| Q1 25 | 2.81× | — | ||
| Q4 24 | 8.77× | — | ||
| Q3 24 | 2.36× | — | ||
| Q2 24 | 1.52× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FRT
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
